Download MendeleyDesign of Selective sPLA2-X Inhibitor (-)-2-{2-[Carbamoyl-6-(trifluoromethoxy)-1H-indol-1-yl]pyridine-2-yl}propanoic Acid.
Giordanetto, F., Knerr, L., Nordberg, P., Pettersen, D., Selmi, N., Beisel, H.G., de la Motte, H., Mansson, A., Dahlstrom, M., Broddefalk, J., Saarinen, G., Klingegard, F., Hurt-Camejo, E., Rosengren, B., Wikstrom, J., Wagberg, M., Brengdahl, J., Rohman, M., Sandmark, J., Akerud, T., Roth, R.G., Jansen, F., Ahlqvist, M.(2018) ACS Med Chem Lett 9: 600-605
- PubMed: 30034586
- DOI: https://doi.org/10.1021/acsmedchemlett.7b00507
- Primary Citation of Related Structures:
6G5J - PubMed Abstract:
A lead generation campaign identified indole-based sPLA 2 -X inhibitors with a promising selectivity profile against other sPLA 2 isoforms. Further optimization of sPLA 2 selectivity and metabolic stability resulted in the design of (-)- 17 , a novel, potent, and selective sPLA 2 -X inhibitor with an exquisite pharmacokinetic profile characterized by high absorption and low clearance, and low toxicological risk. Compound (-)- 17 was tested in an ApoE -/- murine model of atherosclerosis to evaluate the effect of reversible, pharmacological sPLA 2 -X inhibition on atherosclerosis development. Despite being well tolerated and achieving adequate systemic exposure of mechanistic relevance, (-)- 17 did not significantly affect circulating lipid and lipoprotein biomarkers and had no effect on coronary function or histological markers of atherosclerosis.
Organizational Affiliation:
Medicinal Chemistry, Translational Sciences, Bioscience, and Drug Metabolism and Pharmacokinetics, Cardiovascular and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg SE-431 89, Sweden.
